Using CRISPR technology to understand how different RNA forms function in cancer
A CRISPR/Cas13 approach for identifying individual transcript isoform function in cancer
['FUNDING_R21'] · NEW YORK GENOME CENTER · NIH-10671680
This study is looking at how certain RNA molecules might play a role in cancer growth and why some treatments don't work, using a new method to carefully reduce these RNA levels in cancer cells to see what happens, all with the hope of finding better ways to fight cancer.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK GENOME CENTER (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10671680 on ClinicalTrials.gov |
What this research studies
This research investigates how specific RNA molecules, known as transcript isoforms, contribute to cancer development and treatment resistance. By employing a novel CRISPR/Cas13 technique, the study aims to selectively reduce the expression of these RNA forms in cancer cells, allowing researchers to observe their individual functions. This approach is designed to be more precise than traditional methods, minimizing unintended effects on other RNA molecules. The ultimate goal is to enhance our understanding of cancer biology and improve therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who are interested in understanding the molecular mechanisms of their disease.
Not a fit: Patients with non-malignant conditions or those not diagnosed with cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted cancer therapies that specifically address the roles of different RNA forms in tumor growth and drug resistance.
How similar studies have performed: While CRISPR technology has shown promise in various applications, this specific approach targeting transcript isoforms in cancer is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK GENOME CENTER — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KNOWLES, DAVID ARTHUR — NEW YORK GENOME CENTER
- Study coordinator: KNOWLES, DAVID ARTHUR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer